Due to the corona pandemic, POTS, CFS/ME, CRPS, SFN diagnostics are currently only performed in our laboratory at approximately 2 to 3-week intervals. The next sample determination is scheduled for April 15th, 2021. Please send us your sample with the completed request form (important: email address and signature). For guide of blood preparation, please click here!…Details
After a successful certification audit at TÜV Rheinland in December 2020, we have now received the new DIN EN ISO 13485:2016 certificate. This means that we are now optimally prepared for the IVDR and have made the change to a certifier that will continue to be approved as a Notified Body for in vitro diagnostics…Details
Please note: Between 19.12.2020 and 03.01.2021 our laboratory will be closed. During this time, neither sample acceptance nor the sending of results is possible. We wish our customers and business partners a Merry Christmas and a good start into the New Year! Thank you for the good and successful cooperation, for your trust and loyalty!Details
The current patent covers the test developed by us in cooperation with the Charité Berlin, AG Scheibenbogen, for the quantitative determination of antibodies directed against the ß-adrenergic receptor. A high antibody titer is an indication of the presence of chronic fatigue syndrome (CFS) and thus plays a decisive role in its diagnosis.
The event is web-based. You do not need to download anything. Also the possibility to participate in the live chat is anonymous or your names are only visible to the speakers. This training is implemented according to the EU-DSGVO! The team of speakers would be very pleased about your interest and participation. You can register…Details
We are pleased to inform you that our latest product developments are now available on request. You can find further information here.
Prof. Dr. Jonas Bergquist, University of Uppsala, Sweden, investigated antibodies against adrenergic receptors (a1, a2, b1, b2, b3) and acetylcholine muscarinergic receptors (M1-5) in two Swedish CFS/ME cohorts. For M3R-Ab and M4R-Ab a significant increase in antibody levels was found in CFS/ME patients compared to controls in both cohorts, for b1-adr-R-Ab and b2-adr-R-Ab only in…Details
The nationwide “Network for Pharma Solutions” (NetPhaSol), consists of 50 competent partners. The 20 research institutions and 30 companies including CellTrend are covering the entire value chain in drug discovery and development. The “Network for Pharma Solutions” (NetPhaSol) starts campaign for networking and cooperation Are you looking for qualified partner for your project? Are…Details